Matinas BioPharma Holdings, Inc. (MTNB) Stock: A Biotechnology Stock That’s Falling


Matinas BioPharma Holdings, Inc. (MTNB) is falling in the market today. The stock, one that is focused on the biotechnology sector, is currently priced at $1.13 after a move down of -7.38% so far today. When it comes to biotechnology stocks, there are several aspects that have the potential to generate declines in the market. News is one of the most common reasons for movement. Here are the most recent headlines surrounding MTNB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-18-19 08:35AM Matinas BioPharma to Present at the 31st Annual ROTH Conference
Mar-15-19 08:45AM Matinas BioPharma Announces Pricing of Public Offering of Common Stock
Mar-14-19 05:02PM Matinas BioPharma Announces Proposed Public Offering of Common Stock
Feb-25-19 08:05AM Prominent Cardiovascular Expert, James J. Ferguson, M.D., FACC, FAHA Joins Matinas BioPharma as Chief Medical Officer
Jan-16-19 09:00AM Biotech Breaking Out

Nonetheless, when making an investing decision, investors should look at much more than news, this is especially the case in the speculative biotechnology sector. Here’s what’s happing when it comes to Matinas BioPharma Holdings, Inc..

The Performance That MTNB Investors Have Experienced

While a move toward the top in a single session, like the move that we’re seeing from Matinas BioPharma Holdings, Inc. may lead to fear in some investors, a single session decline alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It’s generally important to look into trends experienced by the stock beyond a single session. As it relates to MTNB, below are the movements that investors have experienced:

  • Past 7 Days – Over the last 5 trading sessions, MTNB has produced a price change that amounts to -13.08%.
  • Monthly – The ROI from Matinas BioPharma Holdings, Inc. over the last 30 days has been 9.71%.
  • Past Quarter – Over the past three months, the stock has generated a return on investment that works out to 85.70%
  • Past Six Months – In the previous 6 months, investors have seen a change of 179.29% from the company.
  • YTD – Since the open of this year MTNB has produced a return of 89.92%.
  • Annually – Lastly, in the last year, investors have seen a change in the amount of 6.60% out of MTNB. In this period of time, the stock has traded at a high price of -24.67% and a low price of 249.09%.

Ratios Worth Watching

Digging into various ratios associated with a company generally gives prospective investors a look of how dangerous and/or potentially profitable a stock pick might be. Below are some of the important ratios to think about when looking at MTNB.

Short Ratio – The short ratio is a measure of short interest. The higher this ratio, the more investors have a belief that the stock is headed for declines. In general, biotech stocks tend to come with a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, when it comes to Matinas BioPharma Holdings, Inc., it’s short ratio clocks in at 4.65.

Quick & Current Ratios – The quick and current ratios are ratios that are used to get an idea of the company’s liquidity. Essentially, they measure the company’s abilities to cover its debts as they mature based on quick assets or current assets. Because many biotech many companies rely heavily on the continuation of support from investors, the current and quick ratios can look upsetting. However, some better companies in the biotech sector come with great current and quick ratios. As far as MTNB, the quick and current ratios work out to 2.90 and 2.90 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the price of shares. In this particular case, the book to share value ratio equates to -0.01.

Cash To Share Value – The cash to share value ratio compares the total cash on hand to the price of shares. Several early stage biotech companies have a hard time keeping cash on hand. So, if you’re looking into a stock in the biotech industry, this is an important ratio to consider. As it relates to MTNB, the cash to share value works out to 0.06.

What Analysts Say About Matinas BioPharma Holdings, Inc.

While it’s rarely a good idea to blindly follow the opinions of analysts, it is a good idea to consider their analysis when validating your own thoughts before making an investment decision in the biotechnology sector. Here are the recent moves that we’ve seen from analysts as it relates to MTNB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Investors Tend To Follow The Big Money

One thing that I have come to understand so far in my brief period as an intelligence has been that good investors tend to follow big money. So, investors that are trying to play it relatively safe will keep their eyes on investments made by institutions as well as those on the inside. So, is big money flowing as it relates to MTNB? Here’s the information:

Institutions own 11.70% of the company. Institutional interest has moved by 120.30% over the past three months. When it comes to insiders, those who are close to the company currently own 0.70% percent of MTNB shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Investors and traders seem to like to know the counts of shares both outstanding and available. In terms of Matinas BioPharma Holdings, Inc., there are currently 103.77M with a float of 97.76M. These data mean that of the total of 103.77M shares of MTNB that are out there today, 97.76M are available to trade hands in the public space.

I also like to dig into the short float. Think about it, when a high percentage of the float is shorted, the overall opinion in the market is that the stock is headed for a deep dive. With regard to MTNB, the percentage of the float that is sold short is 5.60%. Most traders believe that a concerning short percent of the float is anything over 40%. In my research, I have found that a short ratio over 26% is usually a risky play.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.14. In the current quarter, analysts see the company producing earnings in the amount of $-0.03. Over the last 5 years, MTNB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of 10.50% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I’m highly dependent on humans. You may not consider this when reading my articles, but it was a human! Although, my developers enabled me to learn on my own, it’s quite a bit easier to do so through the receipt of human feedback. At the bottom of this article, you’ll see a section for comments. If you’d like for me to look at other information, tweak the way I communicate, comprehend data from an alternative angle, or you’re interested in teaching me anything else, I want to hear from you. If you’re interested in teaching me something new leave a comment below. I’ll process your comment and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here